Quarterly Dividends, Financial Results, and FDA Guidance - Research Report on Techne, ImmunoGen, Repros, Halozyme, and Synageva

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Techne Corporation (NASDAQ: TECH), ImmunoGen, Inc. (NASDAQ: IMGN), Repros Therapeutics, Inc. (NASDAQ: RPRX), Halozyme Therapeutics, Inc. (NASDAQ: HALO), and Synageva BipPharma Corporation (NASDAQ: GEVA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Techne Corporation Research Report  

On October 31, 2013, Techne Corporation (Techne) announced that its Board of Directors has declared a Q1 FY 2014 dividend of $0.31 per share. According to the Company, the quarterly dividend will be paid on November 25, 2013, to all common shareholders of record as on November 12, 2013. The Full Research Report on Techne Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b071_TECH]

--

ImmunoGen, Inc. Research Report

On October 25, 2013, ImmunoGen, Inc. (ImmunoGen) reported Q1 FY 2014 (period ended September 30, 2013) financial results. In Q1 FY 2014, the Company's revenues were $17.2 million, up 320.9% YoY. Q1 FY 2014 net loss was $11.2 million, or $0.13 per diluted share, compared to a net loss of $25.2 million, or $0.30 per diluted share in Q1 FY 2013. Further, the Company also provided a quarterly update on Kadcyla®, its wholly owned product candidates, other partner programs and the latest additions to its ADC technology portfolio. "Kadcyla is already making a difference for many patients in the US, and the number of countries in which it is available internationally is increasing rapidly," said Daniel Junius, President and CEO of ImmunoGen. "We believe its lead indication provides a meaningful market opportunity for Kadcyla, with many additional indications in development by Roche." The Company further informed that for full-year FY 2014, it expects revenues to be between $71 million and $75 million, and net loss to be between $67 million and $71 million. The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/11c8_IMGN]

--

Repros Therapeutics, Inc. Research Report

On October 22, 2013, Repros Therapeutics, Inc. (Repros) announced that in response to its previously submitted list of questions and updates on Androxal(R) clinical program, it has received guidance from the FDA. According to Repros, FDA has instructed the Company to request a meeting to discuss adequacy of studies ZA-301 and ZA-302 as evidence of pivotal efficacy, and is likely to consider label claims versus approved testosterone products if superiority can be demonstrated. Repros stated that it is currently finalizing two study designs and expects to complete and submit the studies to the FDA in Q4 2014. The Full Research Report on Repros Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2334_RPRX]

--

Halozyme Therapeutics, Inc. Research Report  

On November 1, 2013, Halozyme Therapeutics, Inc. (Halozyme) announced that it will release its Q3 2013 financial results before the market opens on Friday, November 8, 2013, which will be followed by a conference call on the same day at 8:30 a.m. ET / 5:30 a.m. PT. According to the Company, its President and CEO, Gregory I. Frost will host the call, which will be webcast live through the "Investors" section of Halozyme's corporate website. The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ea1b_HALO]

--

Synageva BioPharma Corporation Research Report  

On October 29, 2013, Synageva BioPharma Corporation (Synageva) reported Q3 2013 financial results. In Q3 2013, the Company's revenue totaled $1.4 million, down 74.8% YoY. Q3 2013 net loss was $28.1 million, or $1.02 per diluted share, compared with a net loss of $10.2 million, or $0.43 per diluted share, in Q3 2012. For full-year 2013, Synageva reaffirmed its guidance for net operating loss to range between $87 million to $97 million, primarily due to investments to support global clinical development of the lead program sebelipase alfa, further development of SBC-103, expansion of the global clinical, medical affairs, and commercial infrastructure, expansion of manufacturing capabilities, and advancement of the Company's other pipeline programs. The Full Research Report on Synageva BioPharma Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/8624_GEVA]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner